Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13833260 | 1.00 | MEN1 (0.33) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL1467682 | 1.00 | MEN1 (0.33) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL3936793 | 0.90 | MEN1 (0.35) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL1035235 | 0.90 | MEN1 (0.35) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL13739930 | 0.90 | MEN1 (0.35) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL28268357 | 0.89 | MEN1 (0.38) | MEN1MAPK1KMT2AGAABTK | |
| Hydrochloric Acid SCHEMBL20137871 | 0.89 | MEN1 (0.34) | MEN1MAPK1KMT2ARORCGAA | |
| Hydrochloric Acid SCHEMBL29182805 | 0.89 | MEN1 (0.34) | MEN1MAPK1KMT2ARORCGAA | |
| Hydrochloric Acid SCHEMBL20137760 | 0.89 | MEN1 (0.34) | MEN1MAPK1KMT2ARORCGAA | |
| SCHEMBL24690393 | 0.88 | RORC (0.35) | MEN1MAPK1KMT2ARORCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION INC (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025236100-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2025-11-20 | — | — | WO | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250034167-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2024249950-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240140933-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-05-02 | — | — | US | disclosed |
| EP-4341252-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. Hoffmann-La Roche AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| CN-117321042-A | Oxodihydro indole compounds for the treatment of inflammatory diseases or cancers | 豪夫迈·罗氏有限公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023235618-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2022243346-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-11-24 | — | — | WO | disclosed |
| WO-2017076349-A1 | LONG-ACTING DIPEPTIDYL PEPTIDASE-IV INHIBITOR, APPLICATION THEREOF, AND PREPARATION METHOD THEREFOR | 四川科伦博泰生物医药股份有限公司 | 2017-05-11 | — | — | WO | disclosed |
| US-20110009433-A1 | BICYCLIC PYRROLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2264034-A1 | BICYCLIC PYRROLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MEN1 166/4885MAPK1 670/4885KMT2A 2720/4885 |
| US-20110009433-A1 | BICYCLIC PYRROLE COMPOUND | HPD, DPYD, PPIP5K2 | MEN1 3501/4885MAPK1 4625/4885KMT2A 3226/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | MEN1 34/4885MAPK1 378/4885KMT2A 2624/4885 |
| US-20250034167-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MEN1 240/4885MAPK1 457/4885KMT2A 2535/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MEN1 166/4885MAPK1 670/4885KMT2A 2720/4885 |
| US-20240140933-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | IL1B, IL1A, IL1R1 | MEN1 281/4885MAPK1 753/4885KMT2A 2242/4885 |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | MEN1 166/4885MAPK1 670/4885KMT2A 2720/4885 |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | MEN1, MLLT1, MSI2 | MEN1 1/4885MAPK1 1983/4885KMT2A 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.